Enhanced LSD1 expression has been linked to tumour progression56, 57, 58, 59 and can even prime cells for transformation.60 Consequently, clinical trials are currently ongoing to implement LSD1 inhibitors for the treatment of refractory small cell lung cancer (NCT02034123) and acute myeloid leukaemia (NCT02177812, NCT02273102 and NCT02261779). Here, KDM1A is linked to small cell lung carcinoma.